Similar articles

• Randomized phase II trials: misleading and unreliable.

  Stewart DJ. Stewart DJ. J Clin Oncol. 2010 Nov 1;28(31):e649-50; author reply e651-3. doi: 10.1200/JCO.2010.31.3254. Epub 2010 Sep 20. J Clin Oncol. 2010. PMID: 20855829 No abstract available.
• Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.

  El-Maraghi RH, Eisenhauer EA. El-Maraghi RH, et al. J Clin Oncol. 2008 Mar 10;26(8):1346-54. doi: 10.1200/JCO.2007.13.5913. Epub 2008 Feb 19. J Clin Oncol. 2008. PMID: 18285606 Review.
• Criticism of tumor response criteria raises trial design questions.

  Twombly R. Twombly R. J Natl Cancer Inst. 2006 Feb 15;98(4):232-4. doi: 10.1093/jnci/djj086. J Natl Cancer Inst. 2006. PMID: 16478740 No abstract available.
• Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.

  Suman VJ, Dueck A, Sargent DJ. Suman VJ, et al. Cancer Invest. 2008 Jun;26(5):439-44. doi: 10.1080/07357900801971057. Cancer Invest. 2008. PMID: 18568764 Review. No abstract available.
• Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group.

  Gray R, Manola J, Saxman S, Wright J, Dutcher J, Atkins M, Carducci M, See W, Sweeney C, Liu G, Stein M, Dreicer R, Wilding G, DiPaola RS. Gray R, et al. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):1966-9. doi: 10.1158/1078-0432.CCR-05-1136. Clin Cancer Res. 2006. PMID: 16609005 Review.